Key result
Critical evidence gaps in pediatric cardio-oncology leave childhood cancer survivors underdiagnosed and undertreated for CV risks.
Why the study?
Cardiotoxicity is the leading cause of non-relapse morbidity and mortality in childhood cancer survivors, but significant evidence gaps hinder optimal care and cause practice variability.
This review highlights the critical evidence gap in pediatric cardio-oncology and calls for international collaborative research to improve cardiovascular outcomes in childhood cancer survivors.
Improved survival rates for paediatric cancer patients represent a major medical achievement, but they have simultaneously brought the long-term sequelae of oncological treatments into sharp focus. Cardiotoxicity stands out as one of the most serious complications, being the leading cause of non-relapse-related morbidity and mortality among childhood cancer survivors. This comprehensive review analyses the current landscape, highlighting the significant gap in evidence that hinders optimal care. This paper constitutes a comprehensive narrative and scoping review based on a critical analysis of current clinical guidelines, landmark studies, and consensus papers in paediatric cardio-oncology. Crucially, it assesses the heterogeneity and limitations of existing evidence regarding standardized surveillance protocols, primary prevention strategies, and acute/late-onset cardiovascular complication management. The review then identifies and critically discusses key areas for future research and clinical development. A critical gap in evidence persists in paediatric cardio-oncology, leading to significant variability in clinical practice and the underdiagnosis/undertreatment of cardiovascular risk factors in this vulnerable population. To bridge this gap, there is an urgent need for international collaborative research. The overarching goal is to transform paediatric cardio-oncology into a predictive and preventive speciality, ensuring that all childhood cancer survivors achieve not only extended life expectancy but also improved cardiovascular quality of life.
No takes yet. Share an insight, caveat, or question.
Correra et al. (2026) conducted a review in Cardiotoxicity in childhood cancer survivors. A critical gap in evidence persists in paediatric cardio-oncology, leading to significant variability in clinical practice and the underdiagnosis of cardiovascular risk factors in cancer survivors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: